Please find enclosed herewith Financial Results as on 30.09.2025 for your reference.

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-11.8%Reaction day

₹250.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-11.7% vs market

Medical Equipment & Supplies peers, median of 13sector+0.0%-11.8% vs sector

On the reaction day the stock moved 11.7 pts less than Nifty Microcap 250 and 11.8 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-11.8-0.1-11.7+0.0-11.8

Next day

-7.2+0.5-7.7-1.4-5.8

-10.0-0.3-9.7-2.7-7.3

—-0.5—-3.9—

-12.0-0.8-11.2-3.4-8.6

-16.0-2.3-13.7-5.2-10.8

-18.0-2.8-15.2-5.6-12.4

15d

-1.7-4.9+3.1-4.2+2.5

-14.0-4.7-9.3-3.8-10.2

-34.0-7.7-26.3-10.4-23.6

-30.0-7.8-22.2-11.6-18.4

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Royal Sense Limited posted strong top-line growth for H1 FY26 (Apr–Sep 2025). Standalone revenue from operations rose ~87% YoY to ₹2,075.76 lakhs (vs ₹1,107.30 lakhs in H1 FY25), with PAT almost flat at ₹195.31 lakhs (vs ₹192.56 lakhs). On a consolidated basis (includes wholly-owned subsidiary Stergic Retail), revenue jumped ~97% YoY to ₹4,348.34 lakhs and PAT grew ~71% to ₹405.60 lakhs. However, standalone EBITDA margin compressed sharply from ~24.7% to ~14.0% as input costs and other expenses scaled up faster than revenue. Operating cash flow turned negative at ₹-16.66 lakhs standalone and ₹-1,299.15 lakhs consolidated, mainly due to a large build-up in trade receivables and inventory. The auditor (CND & Associates) issued an unmodified review opinion, and the utilization certificate confirms proceeds from the March–May 2025 preferential issue have been fully deployed for working capital and general corporate purposes.

Likely market impact

Strong revenue expansion (boosted by subsidiary consolidation) is positive, but the steep standalone margin compression and negative operating cash flow on a much larger working-capital base are red flags. Shareholders should watch for margin recovery and improvement in receivables/inventory collection in coming periods.